|
NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500
Friday, November 21, 2008
Attributes its Revenue Growth to Increased Patient Adoption and Clinical Support
LAWRENCE, Mass., Nov. 21 /PRNewswire-FirstCall/ -- NxStage Medical, Inc.
(Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today
announced that it ranked 14th on Deloitte's 2008 Technology Fast 500, a
ranking of the 500 fastest growing technology, media, telecommunications and
life sciences companies in North America. Rankings are based on percentage of
fiscal year revenue growth over five years, from 2003-2007. NxStage Medical,
Inc. grew more than 20,000 percent during this period.
NxStage Medical's CEO, Jeffrey H. Burbank, credits the significant health
and quality of life benefits experienced by patients using NxStage's
innovative System One for home hemodialysis therapy, the cost and operational
advantages of the System One within the critical care market, as well as the
strength of the Company's value-added in-center offerings for its significant
revenue growth over the past five years.
"Each company on Deloitte's Technology Fast 500 is an innovator with an
exceptional five-year track record of growth," said Phil Asmundson, Deloitte
LLP vice chairman and national managing partner for Technology, Media and
Telecommunications. "NxStage has earned its position among the fastest growing
companies in North America, and we are proud to honor this important
accomplishment."
Fast 500 Selection and Qualifying Criteria
The Fast 500 ranks the fastest growing technology, media,
telecommunications and life sciences companies in North America. It is
compiled from Deloitte's regional North American Fast 50 programs, nominations
submitted directly to the Fast 500, and public company database research.
Companies are selected based on percentage revenue growth from 2003 to 2007.
Entrants must own proprietary intellectual property or proprietary
technology that contributes to a significant portion of the company's
operating revenues or devote a significant proportion of revenues to research
and development of technology. Using other companies' technology or
intellectual property in a unique way does not qualify. Base-year operating
revenues must be at least $50,000 USD or $75,000 CD, and current-year
operating revenues must be at least $5 million USD or CD. Companies must be in
business a minimum of five years, and they must be headquartered within North
America.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company,
headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and
markets innovative dialysis systems for the treatment of end-stage renal
disease, or ESRD, and acute kidney failure. For more information on NxStage
and its products, please visit the company's website at
http://www.nxstage.com.
About Deloitte
As used in this document, "Deloitte" means Deloitte LLP. Please see
http://www.deloitte.com/about for a detailed description of the legal
structure of Deloitte LLP and its subsidiaries.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are forward-looking,
and the words "anticipate," "believe," "expect," "estimate," "plan," and
similar expressions are generally intended to identify forward-looking
statements. All forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond NxStage's control, which may cause
actual results, performance, or achievements to differ materially from
anticipated results, performance or achievements, including market acceptance
and demand for the NxStage System One, growth in home hemodialysis, and
certain other factors that may affect future operating results and which are
detailed in NxStage's filings with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended September
30, 2008. NxStage is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements, whether as a
result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
VP, Investor Relations
NxStage Medical, Inc.
ksheppard@nxstage.com
SOURCE NxStage Medical, Inc.
|
|
|
|
 |
Banks ‘run system of virtual extortion’ | Jan 8, 2009
|
|
Microsoft's Ballmer: Windows 7 is nearly final | Jan 8, 2009
|
|
Brave techies can try Microsoft's new Windows 7 | Jan 8, 2009
|
|
Mediation board declares Delta, NWA a single system | Jan 8, 2009
|
|
WMS Software supports Oracle and SQL Server platforms. | Jan 8, 2009
|
|
Latest Windows operating system ready | Jan 8, 2009
|
|
The Princeton Review and USA TODAY Present The Princeton Review's 100 'Best Value Colleges for 2009' | Jan 8, 2009
|
|
Online Reputation Management Important For Small Businesses Too | Jan 8, 2009
|
|
Microsoft Research Helps Novice Musicians Discover Their Inner Songwriters | Jan 8, 2009
|
|
Microsoft Mediaroom Gets More Power and Gives TV a Reverse Gear | Jan 8, 2009
|
|
|
